Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas
Authors:
- Michelle HermistonMHMichelle Hermiston
- Carlos Rodriguez‐GalindoCRCarlos Rodriguez‐Galindo
- Kenneth L. McClainKMKenneth L. McClain
- on behalf of the North American Consortium for HistiocytosisOHon behalf of the North American Consortium for Histiocytosis
- 25 September 2017
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (1)
Abstract
Central nervous system (CNS) involvement in Langerhans cell histiocytosis (LCH) can include mass lesions of the hypothalamic pituitary axis, choroid plexus, cerebrum, and cerebellum or magnetic resonance imaging (MRI) signal abnormalities of the cerebellum, pons, and basal ganglia. The term neurodegenerative (ND) CNS‐LCH has been given to the MRI signal abnormalities and neurologic dysfunction, although initially patients may have no clinical symptoms. Standardized evaluations to better understand the natural history and response to therapy are needed. We propose guidelines for clinical, radiologic, and physiologic tests as a framework for developing the best methods of evaluation, which can then be tested in prospective treatment protocols.Keywords
Funding Information
- St. Baldrick's Foundation (318937)
This publication has 78 references indexed in Scilit:
- Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosisBlood, 2016
- Genomic Alterations in Langerhans Cell HistiocytosisHematology/Oncology Clinics of North America, 2015
- Cell(s) of Origin of Langerhans Cell HistiocytosisHematology/Oncology Clinics of North America, 2015
- Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 studyBlood, 2015
- How I treat Langerhans cell histiocytosisBlood, 2015
- Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioningBritish Journal of Haematology, 2015
- Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?British Journal of Haematology, 2014
- BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsJournal of Experimental Medicine, 2014
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Langerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative DiseaseNew England Journal of Medicine, 1994